Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know
Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00.
Shares of Pacific Biosciences are trading down 2.74% over the last 24 hours, at $5.68 per share.
Benzinga ·